For research use only. Not Intended for Therapeutic Use!
|We would like to match the lowest price on market if possible.|
Tetrabenazine ((+)-) is a reversible inhibitor of vesicular monoamine transporter 2 (VMAT-2), inhibits transport by VMAT2 with 10-fold greater potency than transport by VMAT1.
In vitro: Tetrabenazine ((+)-) inhibit the activity of the transporter but appear to interact differently with the protein.  Tetrabenazine ((+)-) inhibits reserpine binding to the transporter, suggesting that the sites may interact in an allosteric manner. 
In vivo: 0.9% saline (80%) and dimethylsulfoxide (DMSO) (20%). Tetrabenazine ((+)-) blocks dopamine (DA) storage and depletes striatal DA; Tetrabenazine ((+)-) was shown to induce tremulous jaw movements (TJMs) in rats and mice. The reference dose for administration is 2.0 mg/kg.
. Podurgiel SJ et al. The MAO-B inhibitor deprenyl reduces the oral tremor and the dopamine depletion induced by the VMAT-2 inhibitor tetrabenazine. Behav Brain Res. 2016 Feb 1;298(Pt B):188-91.
. Peter D et al. Chimeric vesicular monoamine transporters identify structural domains that influence substrate affinity and sensitivity to tetrabenazine. J Biol Chem. 1996 Feb 9;271(6):2979-86.